Operating expenses for the quarter were $9 million, down from $9.4 million for the prior year period, reflecting our continued disciplined expense management. Research and development expenses were $3.2 million compared to $3.1 million in 2024. With the completion of the prime study, R&D expenses will likely decrease as we focus resources on activities that support commercialization and awareness building. Selling general and administrative expenses were $5.7 million versus $6.3 million in the prior year, reflecting our prudent allocation to targeted commercial initiatives and strategic headcount.

Mar 18, 2026 / CFO / receipt, needs a key / Austin Ertz, CFO | earnings call 2026-03-18 | transcript d4bea8bb-d4c4-4b25-ba93-bd585ce3bee5 | chars 15024-15628 | segment 14